Prostate Cancer Daily

June 10, 2026

Videos

Peer-to-Peer Clinical Conversations

Ten-Year Results of Extended Versus Limited Lymph Node Dissection in High-Risk Prostate Cancer - Jean Lestingi & Matheus Ruggeri

Matheus Ruggeri

Jean Lestingi and Matheus Ruggeri present 10-year follow-up data from their randomized trial of extended versus limited pelvic lymph node dissection.

Radiation to the Primary in De Novo mHSPC - Daniel Spratt

Daniel Spratt

Daniel Spratt reviews data supporting radiation to the primary tumor in metastatic hormone-sensitive prostate cancer.

Beyond the Abstracts

Cost-Effectiveness Analysis of 177Lu-PSMA-617 Versus Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer from a U.S. Health Care Perspective - Beyond the Abstract

Prostate Cancer Outcomes in Immunocompromised Patients: A Systematic Review and Meta-analysis - Beyond the Abstract

Conference Coverage

SNMMI 2026: The REFINE Study – A Prospective Clinical Trial: Uncovering Prostate Cancer Biochemical Recurrence with 18F-Fluciclovine After Negative PSMA PET

ASCO 2026: AcTFirst: A Phase 3 Trial of 225Ac-PSMA-617 + ARPI Versus Standard of Care in Adults with PSMA-Positive mCRPC

ASCO 2026: ProTACT: A First-in-Human, Phase 1 Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, and Anti-Tumor Activity of [225Ac]Ac-FL-020, a PSMA-Targeted Radioconjugate, in Patients with mCRPC

AUA 2026: Comparison of EMBARK and EAU Criteria to Identify High-Risk Patients with Biochemical Recurrence after Radical Prostatectomy

AUA 2026: Implementation of a Multidisciplinary Quality Initiative to Mitigate and Reduce the Side Effects of Androgen Deprivation Therapy (ADT) in Prostate Cancer Patients Based on the Prostate Cancer 360 (PC360) Working Group Recommendations

Articles

Editor Selected Abstracts and Commentaries

Prostate Cancer

Enhanced Telehealth in Prostate Cancer.

Comparison of automated bone scan indexes in patients with prostate cancer: aBSI and BONENAVI.

Salvage prostatectomy for locally recurrent prostate cancer after radiation: a narrative review of indications, outcomes, and surgical advancements.

Real-World Clinical Evaluation of S2,3PSA Test in a Prostate Biopsy Cohort With PSA Level of 4-10 ng/mL.

177Lutetium-PSMA-I&T therapy for metastatic castration-resistant prostate cancer (mCRPC): the first multicenter real-world study of 177Lu-PSMA-I&T in Brazil.

Implementing intervention mapping to tailor the evidence-based PREDIMED intervention for medically underserved prostate cancer patients.

Neoadjuvant Fc-Enhanced Anti-CTLA-4 Targets Tregs to Augment Androgen Deprivation in High-Risk Prostate Cancer: A Randomized Phase I Trial - Beyond the Abstract

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Add us to your address book View this email as a web page Forward to a colleague Manage your subscriptions Unsubscribe

Copyright ©2026 Digital Science Press, LLC